Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density

Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer

(2011) Coya Tapia et al.   HUMAN PATHOLOGY

Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma

(2011) Xiao-han Li et al.   ORAL ONCOLOGY

Downregulated Expression of Inhibitor of Growth 4 (ING4) in Advanced Colorectal Cancers: A Non-Randomized Experimental Study

(2011) Qi You et al.   PATHOLOGY & ONCOLOGY RESEARCH

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Functional impact of cancer-associated mutations in the tumor suppressor protein ING4

(2010) Alberto Moreno et al.   CARCINOGENESIS

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)

(2010) Patricia Pautier et al.   GYNECOLOGIC ONCOLOGY

Down-regulation of ING4 is associated with initiation and progression of lung cancer

(2010) Qiu-shi Wang et al.   HISTOPATHOLOGY

Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian Cancer

(2010) Hiroyuki Nomura et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Decreased Expression of Inhibitor of Growth 4 Correlated with Poor Prognosis of Hepatocellular Carcinoma

(2009) F. Fang et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study

(2009) Jennifer M. Rubatt et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

(2009) Russell J. Schilder et al.   GYNECOLOGIC ONCOLOGY

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced expression and novel splice variants ofING4in human gastric adenocarcinoma

(2009) Ming Li et al.   JOURNAL OF PATHOLOGY

Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis

(2008) Yufeng Xie et al.   CANCER LETTERS

Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

(2008) Russell J. Schilder et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE